Showing 2 of 10 years of data. Sign up free for 5 years of history.
View PlansGufic Biosciences (GUFICBIO) reported revenue of ₹8.20B in FY2025 with net income of ₹696.49M. Total assets stood at ₹11.69B. Net worth was ₹6.01B (₹601 Cr) and free cash flow was ₹470.42M.
Gufic Biosciences Income Statement
Hover the chart icon for year-over-year change.
| Item | Chart | 2024 | 2025 |
|---|---|---|---|
| Revenue | 8.07B | 8.20B | |
| Cost of Rev. Cost of Revenue | -3.90B | -3.75B | |
| Gross Profit | 4.17B | 4.45B | |
| SGA Sales, General & Admin | -2.71B | -3.09B | |
| Op. Income Operating Income | 1.29B | 1.15B | |
| PBT Profit Before Tax | 1.16B | 941.44M | |
| Net Income | 861.36M | 696.49M | |
| Dil. Shares Diluted Shares | 98.52M | 100.28M | |
| Diluted EPS | 8.74 | 6.95 |
Figures in ₹ — millions (M), billions (B), trillions (T). EPS is earnings per share.
Understanding the Income Statement
The income statement shows Gufic Biosciences's revenue and expenses over a period. Revenue minus costs gives gross profit; after operating expenses, interest, and taxes, the remainder is net income. Diluted EPS divides net income by all shares that could exist if options and convertibles were exercised.
Gufic Biosciences Balance Sheet
Hover the chart icon for year-over-year change.
| Item | Chart | 2024 | 2025 |
|---|---|---|---|
| Curr. assets Total current assets | 6.00B | 6.25B | |
| Non-curr. assets Total non-current assets | 4.92B | 5.45B | |
| Total assets | 10.93B | 11.69B | |
| Curr. liabilities Total current liabilities | 3.72B | 3.88B | |
| Non-curr. liab. Total non-current liabilities | 1.88B | 1.81B | |
| Total liabilities | 5.60B | 5.68B | |
| Total equity | 5.33B | 6.01B | |
| Total liab. & eq. Total liabilities & equity | 10.93B | 11.69B |
Figures in ₹ — millions (M), billions (B), trillions (T).
Understanding the Balance Sheet
The balance sheet captures Gufic Biosciences's financial position at a point in time — what it owns (assets), what it owes (liabilities), and the residual value to shareholders (equity). Total assets always equals total liabilities plus equity.
Gufic Biosciences Cash Flow Statement
Hover the chart icon for year-over-year change.
| Item | Chart | 2024 | 2025 |
|---|---|---|---|
| Net Income | 861.36M | 696.49M | |
| Operating CF Cash flow Operating Activities | -74.57M | 1.23B | |
| Capex Investments in PPE | -1.13B | -755.26M | |
| Investing CF Cash flow Investing Activities | -1.02B | -707.77M | |
| Dividend Paid | -9.72M | -10.03M | |
| Financing CF Cash flow Financing Activities | 823.81M | -372.04M | |
| Cash (start) Cash at beginning of period | 286.02M | 11.37M | |
| Cash (end) Cash at end of period | 11.37M | 157.23M | |
| FCF Free Cash Flow | -1.20B | 470.42M |
Figures in ₹ — millions (M), billions (B), trillions (T).
Understanding Cash Flow
The cash flow statement tracks how Gufic Biosciences's cash moves through operations, investing, and financing activities. Free cash flow — operating cash minus capital expenditure — shows what is available to return to shareholders.
Data from audited consolidated filings. For educational purposes only — not investment advice. Last update: Mar-2025
Now find out what Gufic Biosciences is worth
You've seen the statements. A paid plan turns those numbers into a verdict — fair-value estimates, undervalued-stock screening, and ownership signals.
- Fair value from 5 models — DCF, DDM, P/E, P/B & EPS growth
- Undervalued-stock screener across 500+ companies
- Insider trades, bulk deals & promoter shareholding trends
Related Stocks
Zydus Lifesciences (ZYDUSLIFE)
Revenue grew 19.0% to ₹27,658 Cr in FY2026.
Caplin Point (CAPLIPOINT)
Revenue compounded at 22.6% annually over 10 years.
Procter & Gamble Health (PGHL)
Revenue declined 19.1% to ₹945 Cr in FY2025.
Neuland (NEULANDLAB)
Revenue of ₹1,477 Cr in FY2025.
Alkem Lab (ALKEM)
Revenue of ₹13,458 Cr in FY2025.
RPG Life Sciences Limited (RPGLIFE)
Revenue of ₹708 Cr in FY2026.